Targeting ZBP1: How a Cellular Alarm System Could Overcome Cancer Immunotherapy Resistance
核心洞察
ZBP1 (搜索) is an innate immune sensor that detects Z-DNA/Z-RNA structures generated during genomic stress and triggers immunogenic necroptosis in tumor cells.
Therapeutic activation of the ZBP1 (搜索)–RIPK3–MLKL axis may convert immunologically "cold" tumors into "hot" tumors, enhancing immune checkpoint blockade efficacy.
Small-molecule drugs like JTE-607 analogs are being designed to mimic viral stress and induce Z-RNA formation without using live viruses.
A newly published review in Ferroptosis and Oxidative Stress positions Z-nucleic acid-binding protein 1 (ZBP1 (搜索)) as a pivotal innate immune sensor capable of converting genomic stress into potent antitumor immunity. The authors propose that therapeutic activation of the ZBP1 pathway could transform immunologically "cold" tumors into "hot" tumors, offering a novel strategy to overcome resistance to cancer immunotherapy.
The review, authored by Dr. Xiao Zhong, Professor Siddharth Balachandran, and Professor Ting Zhang, synthesizes recent discoveries linking genomic stress sensing to regulated cell death and antitumor immune activation. Originally recognized as an antiviral receptor, ZBP1 (搜索) is now understood to detect Z-DNA and Z-RNA structures generated during endogenous retroelement activation, splicing stress, R-loop formation, viral mimicry, and other forms of cellular stress.
A Host-Originated Alarm System
The mechanism underlying ZBP1 (搜索) activation represents a paradigm shift in understanding innate immune sensing. Rather than directly binding to incoming viral RNA, ZBP1 responds to abnormal RNA produced by the host cell under severe stress. When a virus disrupts the cellular CPSF complex—responsible for cleanly terminating RNA transcription—the cell transcribes genes past their normal stop points, generating overextended RNA strands. Embedded within these strands are ancient viral remnants that fold into a rare, left-handed double-helix structure known as Z-RNA.
"What our cells actually recognize to signal the presence of the virus is an alarm the cell has itself set off, and that's novel," said Dr. Siddharth Balachandran, director of the Center for Immunology at Fox Chase Cancer Center and senior author of the study.
Three experiments validated this host-origin mechanism. First, introducing isolated Z-RNA strands from infected cells into healthy, uninfected cells triggered immediate ZBP1 (搜索)-dependent cell death, proving no live virus is required. Second, introducing only the specific viral proteins responsible for disrupting transcription termination—ICP27 from herpes and NS1 from influenza—generated host Z-RNA buildup and activated the self-destruct switch independently. Third, using pharmaceuticals to block the CPSF complex without any virus present replicated the same Z-RNA accumulation and subsequent cellular self-destruction.
Necroptosis as an Immunogenic Bridge
ZBP1 (搜索)-mediated necroptosis does more than simply kill cancer cells. Upon activation, ZBP1 engages the RIPK1–RIPK3–MLKL signaling axis to trigger this highly inflammatory form of regulated cell death, promoting the release of tumor antigens and damage-associated molecular patterns (DAMPs). This creates conditions that enhance immune surveillance, recruiting dendritic cells, enhancing CD8+ T-cell infiltration, and improving the efficacy of immune checkpoint blockade.
The review further explores the intimate relationship between ZBP1 (搜索) signaling and oxidative stress. Reactive oxygen species (ROS) both promote pathway activation and are amplified during necroptotic cell death, creating a feed-forward interaction that positions oxidative stress as both a regulator and an amplifier of ZBP1-mediated immune signaling.
From Viral Mimicry to Small-Molecule Therapeutics
The therapeutic potential lies in combining viral mimicry strategies with ZBP1 (搜索) activation. Epigenetic modulators, curaxins, and splicing inhibitors can induce accumulation of endogenous Z-form nucleic acids. When coupled with localized ROS-generating approaches or nanomedicine platforms, these strategies may selectively induce immunogenic necroptosis within tumors.
The Fox Chase molecular modeling team is currently designing small molecules engineered to safely induce Z-RNA formation exclusively within tumor masses. The lab is focusing on optimizing analogs of JTE-607, an existing transcription-termination inhibitor, to refine its delivery profile. The ultimate goal is to force non-responsive cancer cells to alter their own RNA transcription, flagging themselves for destruction without ever using a live virus.
Challenges Ahead
Before ZBP1 (搜索)-directed therapies can reach clinical practice, several challenges must be addressed. These include identifying biomarkers to stratify patients according to ZBP1 pathway activity, optimizing combination treatment strategies, understanding tumor-specific regulation of necroptosis, and minimizing unwanted inflammatory toxicity. Integrating genomic stress induction, redox modulation, and precision nanomedicine may ultimately maximize the therapeutic potential of this pathway.
By reframing ZBP1 (搜索) as more than an antiviral sensor, this review positions genomic stress sensing as a central regulator of immunogenic cell death and antitumor immunity, opening a new frontier at the intersection of innate immunity, oxidative stress, and regulated cell death.